Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2007
11/21/2007EP1856098A2 Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity
11/21/2007EP1856097A2 Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
11/21/2007EP1856096A2 Phenylglycinamide derivatives useful as anticoagulants
11/21/2007EP1856095A1 Quinazoline derivatives as tyrosine kinase inhibitors
11/21/2007EP1856094A1 Microcrystalline (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)acetic acid
11/21/2007EP1856093A1 Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives
11/21/2007EP1856092A1 6-heteroaryl-1,2,3,4,4a,10b-hexahydro-phenanthridines as pde-4 inhibitors for the treatment of inflammatory disorders
11/21/2007EP1856090A2 Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
11/21/2007EP1856085A1 Flavonoid compounds and uses thereof
11/21/2007EP1856083A2 Chromen-4-one inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
11/21/2007EP1856082A1 Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
11/21/2007EP1856079A1 Spiro-heterocyclic chromans, thiochromans and dihydroquinolines
11/21/2007EP1856077A1 Piperazine derivatives as glyt1 inhibitors
11/21/2007EP1856076A1 Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
11/21/2007EP1856075A1 Substituted arylamine compounds and their use as 5-ht6 modulators
11/21/2007EP1856074A2 Substituted aryl or heteroarylsulfonylbutanamides for use as anti-inflammatory agents
11/21/2007EP1856072A1 Thiazole derivatives as ppar delta ligands and their manufacturing process
11/21/2007EP1856071A1 Benzoxazocines and their therapeutic use
11/21/2007EP1856070A1 Novel drugs for treating respiratory diseases
11/21/2007EP1856067A1 Crystal forms of 2-(3-fluoro4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol and their use as estrogen receptor modulators
11/21/2007EP1856066A1 Anti-cancer and anti-microbial oxazolidinones and analogues
11/21/2007EP1856065A1 1,2,4-triazine derivatives, preparation and use thereof in human therapy
11/21/2007EP1856062A1 4-oxoquinazolin-3-yl benzamide derivatives for the treatment of cytokine mediated diseases
11/21/2007EP1856061A1 Tetrahydro- and dihydroquinazolinones
11/21/2007EP1856060A1 Substituted 1,1,1-trifluoro-3-[(benzyl)-(pyrimidin-2-yl)-amino]-prop an-2-ol compounds
11/21/2007EP1856059A2 Multimers of pyrimidinone derivatives and their use as human neutrophil elastase inhibitors
11/21/2007EP1856058A2 Phthalazine, aza- and diaza-phthalazine compounds and methods of use
11/21/2007EP1856057A1 Tetrahydroindolone and tetrahydroindazolone derivatives
11/21/2007EP1856052A2 Nk1 antagonists
11/21/2007EP1856051A1 Amorphous lercanidipine hydrochloride
11/21/2007EP1856050A1 Crystalline forms of a biphenyl compound
11/21/2007EP1856049A1 Biphenyl compounds useful as muscarinic receptor antagonists
11/21/2007EP1856048A1 Biphenyl compounds useful as muscarinic receptor antagonists
11/21/2007EP1856046A1 Conjugates of metal complex hydroxypyridin derivatives and biomolecules and the use thereof for producing agents used in nmr diagnosis
11/21/2007EP1856045A1 1-acetic acid-indole derivatives with pgd2 antagonist activity
11/21/2007EP1856044A2 Pyrrole derivatives as dna gyrase and topoisomerase inhibitors
11/21/2007EP1856043A1 1-h-pyrrole-2-carboxamides and imidazole-5-carboxamides and use thereof as fak, kdr and tie2 kinase modulators for the treatment of cancer
11/21/2007EP1856042A2 Substituted gamma lactams as therapeutic agents
11/21/2007EP1856041A1 Crystallisation and purification of glycopyrronium bromide
11/21/2007EP1856040A2 Novel lipoxygenase inhibitors
11/21/2007EP1856031A1 2-arylpropionic acid derivatives and pharmaceutical compositions containing them
11/21/2007EP1856029A1 Crystalline acat inhibitor
11/21/2007EP1856026A1 Purification process
11/21/2007EP1855760A2 Combination therapies using hdac inhibitors
11/21/2007EP1855721A1 Method and composition for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
11/21/2007EP1855704A2 Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer
11/21/2007EP1855698A2 Hydrophobic starch compositions and uses of starch as fuel
11/21/2007EP1855697A2 Oligodeoxyribonucleotides of 4000-10000 dalton for treating tumors
11/21/2007EP1855696A2 9a-carbamoyl-y-aminopropyl- and 9a-thiocarbamoyl-y-aminopropyl-azalides with antimalarial activity
11/21/2007EP1855695A1 Solid pharmaceutical composition comprising telithromycin
11/21/2007EP1855694A2 Antisense composition and method for treating muscle atrophy
11/21/2007EP1855693A1 Azithromycin powder for oral suspension compositions
11/21/2007EP1855692A1 Composition for reducing the exudation of serum proteins
11/21/2007EP1855691A2 The use of thiophosphonoformic acid and nrtis to treat viral infections
11/21/2007EP1855690A2 A tetracycline metal complex in a solid dosage form
11/21/2007EP1855689A1 Pharmaceutical compositions comprising anticholinergics and etiprednol
11/21/2007EP1855688A2 Nitric oxide enhancing diuretic compounds, compositions and methods of use
11/21/2007EP1855687A1 Medicament forms with controlled bioavailability
11/21/2007EP1855686A1 Use of pde7 inhibitors for the treatment of neuropathic pain
11/21/2007EP1855685A2 Mitotic kinesin inhibitors
11/21/2007EP1855684A2 Pharmaceutical compositions of the isolated d- enantiomer of the quinazolinone derivative halofuginone
11/21/2007EP1855683A2 A solid pharmaceutical dosage formulation
11/21/2007EP1855682A2 Aminopterin dosage forms and methods for inflammatory disorders
11/21/2007EP1855681A1 Method of treatment of diarrhea-predominant irritable bowel syndrome in a subject
11/21/2007EP1855680A2 Method of treatment of diarrhea-predominant ibs in a female subject receiving contraceptive therapy
11/21/2007EP1855679A2 Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
11/21/2007EP1855678A2 Use of 3-substituted-2-(diphenylmethy)-1-azabicyclo 2.2.2 octanes for treating mrg-x1 receptor mediated diseases
11/21/2007EP1855677A1 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
11/21/2007EP1855676A1 Tetracyclic amino and carboxamido compounds and methods of use thereof
11/21/2007EP1855675A1 Use of a pyrazole derivative for preparing medicines useful for preventing or treating renal diseases
11/21/2007EP1855674A2 Composition for inhibition of cathepsin k
11/21/2007EP1855673A2 Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
11/21/2007EP1855672A1 Hiv protease inhibitors
11/21/2007EP1855671A1 Oral dosage form comprising rosiglitazone
11/21/2007EP1855670A2 Benzazole potentiators of metabotropic glutamate receptors
11/21/2007EP1855669A1 Liposomal compositions for parenteral delivery of agents
11/21/2007EP1855668A1 Novel method for obtaining a fast-dissolving imidapril powder
11/21/2007EP1855667A1 Pharmaceutical composition comprising an indolylmaleimide derivative
11/21/2007EP1855666A1 Dronabinol compositions and methods of using same
11/21/2007EP1855665A1 Use of phenylacetyl-derivatives for the manufacture of a medicament to treat von hippel-lindau (vhl) disease
11/21/2007EP1855664A2 Mitotic kinesin inhibitors
11/21/2007EP1855663A2 Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
11/21/2007EP1855662A2 Methods and compositions for treating cancer
11/21/2007EP1855661A1 Formulation for aviptadil
11/21/2007EP1855660A1 Non-fibrous transdermal therapeutic system and method for its production
11/21/2007EP1855657A2 Dosage form containing oxycodone and naloxone
11/21/2007EP1855654A1 Tablets comprising a high load of strontium
11/21/2007EP1855650A1 Aqueous topical gel of high stability based on metronidazole and method of preparation
11/21/2007EP1855649A2 Method of treating atherosclerosis, dyslipidemias and related conditions
11/21/2007EP1855648A2 Topical stabilized prostaglandin e compound dosage forms
11/21/2007EP1855531A2 Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
11/21/2007EP1855528A2 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
11/21/2007EP1786442B1 Treatment of neurodegenerative diseases by the use of degs inhibitors
11/21/2007EP1771444B1 Salt of oxalic acid with 5-[4-[2-(n-methyl-n-(2-pyridyl)-amino)ethoxy]benzyl]thiazolidin-2,4-dione and a method of its preparation and its use
11/21/2007EP1761524B1 Phenyl diazepane carboxamides and annelated phenyl piperazine carboxamides containing oxygen and used as dopamine d3 antagonists
11/21/2007EP1758914B1 Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof
11/21/2007EP1718340B1 New effector conjugates, process for their production and their pharmaceutical use
11/21/2007EP1711595B1 Use of polysulphated alginate in cellular matrices
11/21/2007EP1697378B1 Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
11/21/2007EP1670513A4 Use of cox-2 inhibitor to prevent t-cell anergy induced by dendritic cell therapy
1 ... 3494 3495 3496 3497 3498 3499 3500 3501 3502 3503 3504 3505 3506 3507 3508 3509 3510 3511 3512 3513 3514 ... 7860